The effect of Empagliflozine on the Non-Alcoholic Fatty Liver Disease in patients with type 2 diabetes mellitus

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 140 人开始时间: 待定最近更新: 2023年5月1日

试验速览

暂无简介。

•Patients with type 2 diabetes in the age group of 20 to 70 years who are candidates for treatment with Empagliflozine
•No history of using Empaglifozine
•GFR>35ml/min/1.7m2
•HbA1c=7.5%
•Satisfaction of patients or their legal guardians to attend the study and continue it

•History of advanced liver and kidney disease
•Cardiac surgery or angioplasty planned within the last 3 months
•Bariatric surgery in last 2 years and other gastrointestinal surgeries that cause chronic malabsorotion
•Bleeding or any disorder in causing hemolysis or unstable red blood cells(such as malaria)
•Medical history of cancer(except basal cell cancer)or cancer treatment in the last 5 years
•treatment with anti-obesity drugs in the 3 months prior ti informed consent or any other treatment at the time of screening(i.e. surgery;aggressive dieting;etc)that results in an unstable body weight
•current treatment with systemic steroids or any uncontrolled endocrine disorder other than type 2 diabetes
•cinsumtion of alcohol or drugs in the last 3 months
•patients who during the treatment,another drug to control blood sugar was added to their teatment

发起方